Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1Phase 1/2 1

Status

Withdrawn 1Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 10Other hematologic neoplasm 5Lymphoid 3Head & Neck 1Gynecologic 1Gastrointestinal 1

Conditions

Lymphoma, Large B-Cell, Diffuse 13Lymphoma 6Lymphoma, T-Cell, Peripheral 4Lymphoma, Non-Hodgkin 4Recurrence 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Multiple Myeloma 3Lymphoma, Extranodal NK-T-Cell 3Lymphoma, B-Cell 3Leukemia, Myeloid, Acute 3Waldenstrom Macroglobulinemia 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Mantle-Cell 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Lymphocytic, Chronic, B-Cell 2Sarcoma 1Primary Myelofibrosis 1Myelodysplastic Syndromes 1Lymphoma, T-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Prolymphocytic 1Leukemia, Biphenotypic, Acute 1Hodgkin Disease 1Hematologic Neoplasms 1Glioma 1Endometrial Neoplasms 1Central Nervous System Neoplasms 1Brain Neoplasms 1Astrocytoma 1

Interventions

Cyclophosphamide 100Rituximab 82fludarabine phosphate 46Peripheral Blood Stem Cell Transplantation 45fludarabine 43Lenalidomide 35Filgrastim 33Methotrexate 32Cytarabine 32Busulfan 32venetoclax 31Etoposide 31Cyclosporine 30Dexamethasone 29Radiotherapy 28Mycophenolic Acid 28Melphalan 28Bendamustine Hydrochloride 25Antilymphocyte Serum 25Vincristine 24Gemcitabine 24ibrutinib 22Whole-Body Irradiation 22Doxorubicin 20Tacrolimus 19Methylprednisolone 18Bortezomib 18Brentuximab Vedotin 16pembrolizumab 15Prednisone 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recurrence × selinexor × Lymphoid × Clear all
NCT04442022 2026-05-06

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Karyopharm Therapeutics Inc

Phase 2/3 Active not recruiting
501 enrolled
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT04607772 2025-10-03

Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)

Karyopharm Therapeutics Inc

Phase 1/2 Withdrawn
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT07011056 2025-09-19

A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma

Chengdu Zenitar Biomedical Technology Co., Ltd

Phase 3 Recruiting
390 enrolled
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡